INTERIM REPORT JANUARY – SEPTEMBER 2005

• Turnover during the period amounted to SEK 669.1 (585.5) million, an increase of 14 percent. • Operating income amounted to SEK 59.0 (369.8) million. Adjusted for revenues and expenses of a one-time nature, operating income amounted to SEK 69.3 (38.9) million. • Net income after tax amounted to SEK 46.8 (316.3) million. • Earnings per share for the period were SEK 1.89 (12.75). • The very positive development for all products within Hospital Healthcare continues: +53%. • The reorganization in Latin America is completed. Sales in Mexico are being resumed during the fourth quarter. Queries should be addressed to: Erika Kjellberg Eriksson, Vice President and CFO, tel: +46 (0)70-974 90 20 Anne Rhenman, Director Investor Relations and Corporate Communications, tel: +46 (0) 70-974 90 15

About Us

Q-Med is a rapidly growing and profitable biotechnology and medical device company that develops, produces and markets medical implants. Operations focus on four areas, Esthetics, Orthopedics, Uro-Gynecology, and Cell Therapy and Encapsulation.

Subscribe

Documents & Links